Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/37924
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArikan, H-
dc.contributor.authorKaradogan, D-
dc.contributor.authorAkyil, FT-
dc.contributor.authorYuksel, A-
dc.contributor.authorToreyin, ZN-
dc.contributor.authorGurkan, CG-
dc.contributor.authorMarim, F-
dc.contributor.authorEr, Aslı Banu-
dc.contributor.authorÇetin, Nazlı-
dc.date.accessioned2021-02-02T12:39:39Z-
dc.date.available2021-02-02T12:39:39Z-
dc.date.issued2020-
dc.identifier.urihttps://hdl.handle.net/11499/37924-
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2020.20125-
dc.description.abstractAs coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.en_US
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTURKISH THORACIC JOURNALen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCoronavirus disease 2019; treatment; hydroxychloroquine; tocilizumab;en_US
dc.subjectconvalescent plasmaen_US
dc.titleCOVID-19 Treatment at a Glanceen_US
dc.typeReviewen_US
dc.identifier.volume21en_US
dc.identifier.issue6en_US
dc.identifier.startpage438-
dc.identifier.startpage438en_US
dc.identifier.endpage445en_US
dc.identifier.doi10.5152/TurkThoracJ.2020.20125-
dc.relation.publicationcategoryDiğeren_US
dc.identifier.pmid33352100en_US
dc.identifier.scopus2-s2.0-85103141655en_US
dc.identifier.trdizinid429700en_US
dc.identifier.wosWOS:000600070300012en_US
dc.ownerPamukkale University-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeReview-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
438-445.pdf651.52 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

3
checked on Nov 21, 2024

Page view(s)

38
checked on Aug 24, 2024

Download(s)

12
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.